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Background
The native envelope gp160 trimer of HIV-1 is thought to
shield vulnerable epitopes that could otherwise elicit
effectively neutralizing antibodies. However, little is
known about the prevalence of naturally occurring cross-
reactive neutralizing activity in serum of HIV-1 infected
individuals.
Methods
Here we studied 35 participants of the Amsterdam Cohort
Studies on HIV-1 infection (20 long-term non-progressors
(LTNP) and 15 progressors) for the presence of cross-reac-
tive neutralizing activity in their sera at 2 and 4 years after
seroconversion (SC). Neutralizing activity was tested in a
pseudovirus assay, against a panel of HIV-1 envelope var-
iants from subtype A, B, C, and D.
Results
Already at year 2 post-SC, 7 out of 35 individuals (20%)
had cross-reactive neutralizing activity, which increased to
11 individuals (31%) at 4 years post-SC. There was no dif-
ference in the prevalence of cross-reactive neutralizing
serum activity between LTNP and progressors. Interest-
ingly, high plasma viral RNA load and low CD4+ cell
count at set-point were associated with early development
of cross-reactive neutralizing activity. Neutralization titers
in serum increased during the course of infection for 91%
of individuals studied here, albeit less rapidly for those
who did not develop cross-reactive neutralizing activity.
Conclusion
Overall, we here demonstrate a relatively high prevalence
of cross-reactive neutralizing activity in HIV-1 infected
individuals, which increased with duration of infection.
These data may imply that immunogenicity of the native
envelope spike of HIV-1 for eliciting cross-reactive
humoral immune responses may be better than previ-
ously anticipated.
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